Retinitis Pigmentosa Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, NDA Approval, Epidemiology, Medication, Pipeline and Companies by DelveInsight
"Retinitis Pigmentosa Drugs Market"
Retinitis Pigmentosa Companies such as Nanoscope Therapeutics, Gensight Biologics, 4D Molecular Therapeutics, Johnson & Johnson, MeiraGTx, Beacon Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight, jCyte, Endogena Therapeutics, ProQR Therapeutics, and Aldeyra Therapeutics and others.
(Albany, USA) DelveInsight's ' Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast 2034 ' report delivers an in-depth understanding of historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
The Retinitis Pigmentosa market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Retinitis Pigmentosa market size from 2020 to 2034, segmented by seven major markets. The Retinitis Pigmentosa Market Report also covers current Retinitis Pigmentosa treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Retinitis Pigmentosa market.
Key Takeaways from the Retinitis Pigmentosa Market Report
In the US, the total number of prevalent cases of retinitis pigmentosa were ~113,000 in 2023.
Nonsyndromic retinitis pigmentosa is more prevalent than syndromic retinitis pigmentosa with ~65% cases of total retinitis pigmentosa.
X-linked retinitis pigmentosa in the US acoounted for ~16,000 prevalent cases in 2023.
Germany has the most cases among EU4 and UK, whereas the UK has the fewest.
RPE65-linked IRD account for about 3–16% of Leber congenital amaurosis and approximately 0.6–6% of retinitis pigmentosa.
The leading Retinitis Pigmentosa Companies such as Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, Gensight Biologics, 4D Molecular Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight, jCyte, Endogena Therapeutics, ProQR Therapeutics, and Aldeyra Therapeutics and others.
Promising Retinitis Pigmentosa Therapies such as Botaretigene sparoparvovec, AGTC-501, GS030, 4D 125, CTx PDE6B, OCU 400, EA-2353, Ultevursen, ADX 2191, and others.
June 2024:- Rolfs Consulting und Verwaltungs-GmbH (RCV)- Participants at risk for a syndromic or a monogenic genetic obesity, incl. participants clinically diagnosed with Bardet-Biedl-Syndrome (BBS).
May 2024:- PYC Therapeutics- The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11.
May 2024:- Janssen Pharmaceutical- Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR). The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).
Discover which therapies are expected to grab the Retinitis Pigmentosa Market Share @ Retinitis Pigmentosa Market Outlook
Retinitis Pigmentosa Overview
Retinitis Pigmentosa (RP) is a group of genetic disorders that cause progressive degeneration of the retina, the light-sensitive tissue at the back of the eye. This condition primarily affects the photoreceptor cells, namely rods and cones, leading to a gradual loss of vision. Initially, individuals with RP experience difficulty seeing in low light or at night (nyctalopia) and a reduction in peripheral vision, often described as tunnel vision. As the disease progresses, it can lead to central vision loss, making tasks like reading or recognizing faces challenging. RP is typically inherited and can result from mutations in any of more than 50 different genes. While there is currently no cure, various treatments, including vitamin A supplementation, retinal implants, and gene therapy, are being explored to slow the progression of the disease and improve patients' quality of life.
Retinitis Pigmentosa Epidemiology Segmentation
Total Retinitis Pigmentosa Diagnosed Prevalent Population
Retinitis Pigmentosa Gender-Specific Diagnosed Prevalence
Retinitis Pigmentosa Type-Specific Diagnosed Prevalence
Sub-Type Specific Diagnosed Prevalence of Syndromic and Systemic Retinitis Pigmentosa
Sub-Type Specific Diagnosed Prevalence of Non-Syndromic Retinitis Pigmentosa
Download the report to understand which factors are driving Retinitis Pigmentosa Epidemiology trends @ Retinitis Pigmentosa Epidemiological Insights
Retinitis Pigmentosa Treatment Landscape
With only one approved therapies like LUXURNA, prompting exploration of off-label and symptomatic treatments, managing this progressive condition involves best supportive care, genetic counseling, and adaptive strategies. The potential therapies in the Retinitis Pigmentosa pipeline, including AGTC-501, Botaretigene sparoparvovec, MCO-010, GS030, ADX-2191, jCell, EA-2353, and others, are advancing through different stages of clinical development, offering promising avenues for effective Retinitis Pigmentosa treatments.
Retinitis Pigmentosa Marketed Drugs
LUXTURNA: Sparks Therapeutics (Roche)/Novartis
LUXTURNA (AAV2-hRPE65v2; voretigene neparvovec), known as voretigene neparvovec-rzyl, is a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene. It provides a copy of the RPE65 gene to act in place of the mutated RPE65 gene. This working gene can restore vision and improve sight. The drug is administered as a subretinal single injection below the retina in patients who have confirmed RPE65 mutations and viable retinal cells. The drug was developed and commercialized in the US by Spark Therapeutics. In Europe, Novartis is currently marketing LUXTURNA as per a licensing agreement covering the development, registration, and commercialization rights of LUXTURNA in markets outside the US.
Retinitis Pigmentosa Emerging Drugs
Botaretigene sparoparvovec: Johnson & Johnson Innovative Medicine /MeiraGTx
Botaretigene sparoparvovec (bota-vec) is designed to treat the most common form of X-linked retinitis pigmentosa (XLRP) caused by mutations in the eye-specific form of the RPGR gene called RPGR open reading frame 15 (RPGR ORF15). Both rods and cones photoreceptors require RPGR ORF15 to function.The Phase I/II clinical trial of bota-vec in adult and pediatric patients is complete, and the Phase III Lumeos clinical trial completed enrollment in 2023. AAV-RPGR has received Fast Track and Orphan Drug designations from the FDA, as well as PRIME, ATMP, and Orphan Medicinal Product designations from the EMA. Currently, the drug is in the Phase III stage of its development for the treatment of X-linked Retinitis Pigmentosa.
MCO-010: Nanoscope Therapeutics
Nanoscope's MCO-010 gene therapy utilizes a convenient and well-established intraocular injection for delivery of a gene that encodes for the ambient light-sensitive MCO protein into retinal cells. These therapies are intended to enable retinal cells to detect light so that patients with retinitis pigmentosa or Stargardt disease may see again. MCO-010, is in clinical development for retinitis pigmentosa (RP) and Stargardt disease, which are two rare retinal diseases that cause blindness. MCO-010, recently reported topline results from the RESTORE Phase IIb multicenter, randomized, double-masked, sham-controlled clinical trial in the US for retinitis pigmentosa. The company has also recently completed the Phase II STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease. MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease.
Download the report to understand which factors are driving growth in Retinitis Pigmentosa domain @ Retinitis Pigmentosa Market Dynamics and Trends
Retinitis Pigmentosa Drug Market
Optogenetics presents an innovative gene therapy overcoming the limitations of traditional approaches. It operates independently of specific genes and proves effective in late-stage diseases characterized by substantial photoreceptor loss. Retinitis pigmentosa is basically an inherited disease leading to a degeneration of the photoreceptor cells, disrupting the normal physiology of phototransduction. This may be autosomal dominant, autosomal recessive, X-linked, or maternally acquired. Mutations in pre-mRNA splicing cause autosomal dominant retinitis pigmentosa. Autosomal recessive RP is caused when two unaffected individuals who are carriers of the same RP-inducing gene in diallelic form can produce offspring with RP. X-linked RP is identified with mutations of six genes most commonly occurring at specific loci in the RPGR and RP2 genes. These multiple mutations are produced, causing the degeneration of photoreceptor cells.
Retinitis Pigmentosa Market Outlook
As more targetable mutations are discovered, and new targeted Retinitis Pigmentosa drugs are developed, patients and Opthamologists will have an expanding array of Retinitis Pigmentosa treatment options. Given the rapid pace of drug approvals, it is important to pause and ensure sufficient data supports the use of specific agents in the appropriate treatment settings, including adjuvant, consolidation, first-line, or subsequent therapy.
Currently, LUXTURNA (voretigene neparvovec) is the only approved therapy for retinitis pigmentosa and is only authorized for the treatment of a small subpopulation of patients that have the RPE65 mutation. LUXTURNA gene therapy is designed for both adult and pediatric patients experiencing vision loss from Inherited Retinal Disease (IRD). Companies that focus on both adult and pediatric patients are likely to have a larger patient pool. Some key players pursuing this approach include Beacon Therapeutics (AGTC-501), MeiraGTx/Janssen Research & Development (Botaretigene sparoparvovec), 4D Molecular Therapeutics (4D-125), ProQR Therapeutics/Laboratoires Thea (Ultevursen), Coave Therapeutics (CTx-PDE6b), and Ocugen (OCU400).
Retinitis Pigmentosa Market Dynamics
The dynamics of the retinitis pigmentosa market are expected to change in the coming years. Gene therapy, available in the market, is utilized to address the effects of defective, disease-causing genes by employing engineered viruses, or viral vectors, to deliver a functional gene version into cells. The rising prevalence of retinitis pigmentosa worldwide has spurred pharmaceutical companies to explore this market, aiming for enhanced revenues through specific research and development strategies.
Scope of the Retinitis Pigmentosa Market Report
Coverage- 7MM
Retinitis Pigmentosa Companies- Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, Gensight Biologics, 4D Molecular Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight, jCyte, Endogena Therapeutics, ProQR Therapeutics, and Aldeyra Therapeutics and others.
Retinitis Pigmentosa Therapies- Botaretigene sparoparvovec, AGTC-501, GS030, 4D 125, CTx PDE6B, OCU 400, EA-2353, Ultevursen, ADX 2191, and others.
Retinitis Pigmentosa Market Dynamics: Retinitis Pigmentosa Market Drivers and Barriers
Discover more about Retinitis Pigmentosa Drugs in development @ Retinitis Pigmentosa Clinical Trials Assessment
Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of Retinitis Pigmentosa (RP)
4. Retinitis Pigmentosa Market Overview at a Glance
5. Key Events
6. Epidemiology and Market Forecast Methodology
7. Retinitis Pigmentosa: Disease Background and Overview
8. Treatment of Retinitis Pigmentosa
9. Retinitis Pigmentosa Epidemiology and Patient Population
10. Patient Journey
11. Retinitis Pigmentosa Marketed Drugs
12. Retinitis Pigmentosa Emerging Drugs
13. Retinitis Pigmentosa: Market Analysis
14. Retinitis Pigmentosa Unmet Needs
15. Retinitis Pigmentosa SWOT Analysis
16. Retinitis Pigmentosa KOL Views
17. Retinitis Pigmentosa Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Network
8 minutes ago
- Fashion Network
Printemps hosts Perelman Performing Arts Center announcement of DVF as next Icon of Culture
Having only been in lower Manhattan for under four months, Printemps New York is proving its good neighbor status and dedication to the Financial District. The French retailer opened its doors for an event to kick off the buzz for this fall's annual Perelman Performing Arts Center, aka PAC NYC's Icon of Culture Gala. Hosted by PAC chair and former Big Apple hizzoner Michael R. Bloomberg; supermodel, entrepreneur, and philanthropist, Karlie Kloss; and Printemps Americas CEO, Thierry Prevost, the cocktail announced iconic fashion legend and Légion d'Honneur recipient Diane Von Furstenberg as the 2025 PAC NYC Icon of Culture at the upcoming October black-tie event to benefit the newly opened arts center. The event marks the second Icons of Culture fundraising gala. The kickoff event was held in the new French store—designed by French architect Laura Gonzales that defies the department store moniker— in its famous Red Room shoe salon and adjacent bar, one of five food and beverage locales in the store. While Von Furstenberg was out of town and unable to attend, DVF Studio's CEO, Graziano de Boni, and his wife, Valerie, and VP of philanthropy, Luisella Meloni, showed up in support of the pioneer female fashion designer. Von Furstenberg is being honored not only for her contributions to the city but her 50-year impact on fashion and her role as a mentor and advocate for girls and women around the world. Speaking to a crowd which included Fern Mallis, Derek Blasberg, Drena De Niro, Samantha and Caleigh Perelman, and Born This Way Foundation president and co-founder Cynthia Germanotta, and Lady Gaga's mother. Bloomberg called von Furstenberg "a towering figure in the arts and culture here in New York," adding, "She's one of the most influential names in fashion, an industry at the heart of our city's economy. She's been a tireless advocate for the industry and a generous philanthropist with her leadership on public projects like the High Line and the Statue of Liberty Museum. She's deeply committed to our city, and her support and investment have helped build a bright future here." Following his remarks, a visibly pregnant Karlie Kloss, a longtime collaborator and friend of von Furstenberg, spoke about her relationship with the designer. "I first met Diane when I was 15 years old in New York, and I remember being enamored with her elegance, her confidence, and her style. Diane has been one of my fiercest champions and greatest teachers throughout my career. I've learned so much from her, but especially to be unapologetically myself. She has shown us all what a purposeful life looks like, and I can't think of anyone more deserving of this award," said Kloss. Thierry Prevost, CEO of Printemps Americas, emphasized the brand's commitment to the downtown neighborhood: "Printemps is proud to contribute to the renewal of Lower Manhattan, a neighborhood whose vitality owes much to the vision and leadership of Mike Bloomberg. We're equally honored to host PAC at Printemps New York ahead of their October Icons of Culture Gala. This year, they have named Diane von Furstenberg - an icon of fashion and culture, and a woman whose bold spirit and lasting influence personify the values we stand for - as the 2025 award recipient." Provost reiterated the sentiment of Printemps's chairman Jean-Marc Bellaiche, who spoke to at the store's March opening about the area that "boasts Casa Cipriani, a performing arts center, fashion brands like Altuzarra and the cool crowd over at WSA, another architectural gem, the Beekman Hotel, good schools, green spaces, and Jean Georges Tin Building." At the time, Bellaiche doubled down on his conviction of the area. "We are convinced that this is a neighborhood of tomorrow. It's up and coming. It's more and more residential. The people and businesses that were here are different than 15 years ago. Now, it's not just bankers; it's fashion, it's tech, it's media, and it's all here. It's a vibrant community that is becoming more attractive for any New Yorker," he said. The 108th mayor of New York City was the connector for the event and spearheaded bringing the creatives together. Bloomberg's dedication to the area began when his term started in January of 2002, as the city was still reeling from the 9/11 attacks. The then-mayor and his administration were determined to bring the area back together and make it bigger and better, developing the typically work-only area into a 24-hour neighborhood with housing, parks, and new businesses. Part of the plan was the arts. The idea came to fruition with the help of the Lower Manhattan Development Corporation, who made the first central pledge, and Ronald Perelman, for which it was named. PAC NYC brings vibrant dancers, musicians, artists, filmmakers, and other creators from across New York City for performances and exhibitions.
Economic Times
9 minutes ago
- Economic Times
Far from madding crowds: Good planning, modern tech can prevent deadly stampedes
Hell is empty, and all the devils are here. In India, stampedes have become a routine tragedy, taking a heavy toll on lives and often being man-made. At one time, they were largely confined to religious events, triggered by the fervour of devotees. In recent times, they have also occurred at railway stations and celebrity Bangalore tragedy is a case in point. Meant to celebrate RCB's IPL T20 victory, the event at Chinnaswamy Stadium-which has a capacity of about 35,000-drew an estimated 200,000 to 300,000 people. The inevitable rush, jostling to get in and lack of discipline led to chaos. The resulting stampede left 11 dead and dozens injured. A senior police officer had reportedly flagged the risks before the event, but no action was taken. Every such tragedy is unique. Yet, the reasons cited are almost always the same. Crowds are always 'unexpectedly large', sudden surges are caused by an 'unplanned event' (VIP or celebrity presence, late opening of a gate) and 'insufficient police presence', which result in poor crowd control. Simple system improvements could prevent-or at least mitigate-such tragedies. Now, there is the additional tool of new technology. Tapping its potential, though, requires something uncommon in India: multidisciplinary teams. Such teams must include technologists, from computer programmers to data scientists to sensor and drone experts, and mathematicians. Crucially, they must also have social scientists-particularly sociologists and psychologists-a breed rarely seen on such start with, such a team would collect as much data as possible from past stampedes and large gatherings to build a basic model of crowd dynamics. It would seek to model how and when crowds suddenly surge and events that lead to this getting out of control. Is there a critical mass or crowd density that sparks uncontrolled pushing and panic? Are problems due to choke points or sudden pressure releases (as when a gate is opened, or a celebrity arrives)? Are there patterns of crowd agglomeration and movement? Analytics based on historical data would help create a model to answer these and other questions. Updates from new events, including large crowds and stampedes, would be used to continuously hone and refine the old data may be difficult-but it is possible. It would have to depend on anecdotal data, social media posts, CCTV coverage and mobile video recordings from the events-from the past and in future-may have drone coverage, which would provide additional data. Collating and synthesising from all this, and integrating it with terrain data, local maps (where are the gates?) and weather information (sudden showers or high temperatures can cause stampedes) can best be done by using that is mentioned above about crowds also applies to mobs-a more focused, often more volatile, form of crowd. Handling them poses similar data-based models with insights into human behaviour can make them significantly more accurate and useful. This is where sociologists-who understand group and crowd behaviour-and psychologists (who have insights on individual behaviour) play a vital addition to statistical correlation provided by data analytics and AI, social scientists would provide the cause-and-effect dynamics that are key to preventing such tragedies. In scientific terms, this is adding physics to mathematics. Also, social scientists can suggest what kind of social media messages, or 'nudges', might prevent crowd accumulation or ensure safe behaviour of crowds. With more data, social science, like data analytics, will be able to improve the model, do predictive modelling, even preventive specific things follow from the above: Data is key: Collecting and collating data from all sources is critical. Going forward, new technologies-drones, sensors, big data analytics, AI-must be used. While models based only on statistical data analytics may be fungible, these will not work well here since crowd behaviour is culture-specific. Study crowd behaviour: There's a growing market for large, live events-sports, concerts, political rallies-involving tens of thousands of people. This makes such models vital. Their culture-specificity highlights the need to develop indigenous models, necessitating the involvement of social scientists. Computational sociology: It requires sophisticated and multi-disciplinary research with a degree of mutual understanding between technologists and social scientists. This needs the development of a new discipline: computational sociology. GoI should support the roll out of dedicated courses and fund them. It is worth noting that any successful use of tech for people's benefit requires the involvement of social scientists. Isro demonstrated the advantages through its pioneering multi- and trans-disciplinary teams for the Satellite TV Experiment (SITE) in 1975. Social media key: Given the role of social media in crowd collection and subsequent behaviour (often triggered by rumours or fake news), prompt corrective and pre-emptive posts would help. These can be created and sent out instantaneously by GenAI, which can be integrated into the model. With our population size and culture, large crowds may be unavoidable. However, what the tech-based models can ensure is that crowds do not equal stampedes. That would be one tragedy we could-and should-finally prevent. The writer is chairperson, Indraprastha Institute of Information Technology Delhi (Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Will Royal Enfield's back to the future strategy woo GenZ? We don't have a global legacy, so our products can be tailor-made: IndiGo CEO HSBC's next move could shake up India's venture debt play Everything 'e' won't make you a millionaire. Just look at e-pharmacies Are Indian banks staring at their worst in 7 years? F&O Radar | Deploy Short Strangle in Nifty to benefit from volatility, Theta Stock picks of the week: 5 stocks with consistent score improvement and return potential of more than 28% in 1 year For investors with patience & ability to take moderate risk: 6 mid-cap stocks from different sectors with upside potential up to 36%
Yahoo
9 minutes ago
- Yahoo
Tony Awards 2025: George Clooney Gives Rare Update on His, Amal's Kids
Originally appeared on E! Online What George Clooney's kids are interested in isn't so up in the air. Indeed, as the Ocean's Eleven alum navigates fatherhood with his and wife Amal Clooney's 8-year-old twins Ella and Alexander, he shared insight into their pop culture diet. 'They want to see ,' George told E! News' Keltie Knight during an exclusive interview at the 2025 Tonys red carpet. 'The funniest part is that they have no idea of references. Robert DeNiro will be at the house and they're like 'Who's that?' They don't care.' His little ones, however, do know the cast of Wicked and can't wait to see Cynthia Erivo and Ariana Grande dazzle in Wicked: For Good. As he put it, 'They're looking forward to the second part.' (See every star here.) And for George—who is nominated in the Best Actor in a Play for Good Night, and Good Luck—it helps having Amal by his side at home and in his career. More from E! Online Tony Awards 2025: Katie Holmes Wows During Rare Red Carpet Appearance Tony Awards 2025: See the Complete Winners List (Live Updates) See Kourtney Kardashian and Travis Barker's Rare Public Outing With Son Rocky 'I have this incredible partner who I couldn't be more proud of,' he gushed. 'She's the bravest human being I've ever met in my life. I am deeply proud of her and the fact that she's in any way proud of me, if just, I can't believe how lucky I am.' Something that Amal—who accompanied her husband in a stunning white gown adorned with pearl—is grateful for? George finally returned to his famed salt-and-pepper locks after going dark for his onstage role as Edward R. Murrow. "I had to cut it all out with a weed whacker to get it all," George teased at Radio City Music Hall. "That black hair dye, I had to cut it out. You can't color that." Although the E.R. alum kept the eyebrow-raising hair color for his latest project, he was ready to rid himself of the look as soon as he and the cast took their final bows. 'We do a matinee, and then by the time we go to the Tonys that night, it'll be gone,' he explained on Late Night with Seth Meyers June 3. 'I may have a shaved head.' Meanwhile, Amal has made it clear that she isn't a fan of the look either. "It's not my favorite look, and my wife, she thinks it's funny," George quipped on CBS Mornings in April. 'Honestly, nothing makes you look older than being 63 and dyeing your hair." For more stars at the 2025 Tony Awards, keep reading. Julianne HoughSarah SnookKatie HolmesAlex Winter and Keanu ReevesDaveed DiggsMegan HiltyAnna WintourRosie PerezJustina MachadoRachel SussmanAudra McDonaldDarren CrissJonathan GroffJean SmartNicole ScherzingerSarah PaulsonDanielle BrooksLaufeySarah SnookCole EscolaPhillipa SooCynthia ErivoCole EscolaBryan Cranston For the latest breaking news updates, click here to download the E! News App
